Applications

1836 – Ciltacabtagene autoleucel therapy to treat patients with refractory or relapsed multiple myeloma after at least 1 prior therapy

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Assessment
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Open
  • Outcome Pending

Application details

Applicant

Janssen-Cilag PTY LTD

Reason for application

Funding for a high cost, highly specialised therapy under the National Health Reform Agreement.

Service or technology in this application

Ciltacabtagene autoleucel is a personalised Chimeric Antigen Receptor (CAR) T-cell therapy. It works by extracting a patient's own T-cells, genetically modifying them in a lab to target cancer cells, and reinfusing them into the patient as a single-dose, targeted therapy.

Type: Therapeutic

Medical condition this application addresses

Multiple myeloma is an aggressive cancer that starts in the bone marrow, where blood cells are made. It causes plasma cells, a type of white blood cell that helps fight infection, to develop abnormally. These cancer cells build up in the bone marrow and crowd out healthy cells, reducing the body's ability to make normal blood cells. Symptoms can include bone pain, repeated infections, tiredness and signs of kidney disease. Multiple myeloma often returns after treatment.

This application focuses on relapsed or refractory multiple myeloma after at least one prior therapy in patients who no longer respond to treatment with lenalidomide. 

Consultation survey and deadlines

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.   

Before providing your input, please read our Privacy Notice for MSAC consultation input to ensure you are comfortable with how we will use your input.  

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Bypassing PASC
  • Pre-MSAC consultation deadline: Friday 12 February 2027 11:59 pm AEDT

For other ways to provide input, see how to have your say.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: Bypassing PASC
  • ESC meeting: 11 to 12 February 2027
  • MSAC meeting: 1 to 2 April 2027

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: